Biotech & Genomic Medicine▲2
Alebund Reports 761% Revenue Surge, NMPA Accepts AP301 Application
Alebund Pharmaceuticals announced its 2026 interim results, reporting a 761.2% surge in revenue to RMB104.2 million, driven by licensing revenue of RMB79.3 million from its AP306 deal with R1 Therapeutics and Mircera sales of RMB24.8 million, up 105% year-on-year. The company's net loss narrowed 22.5% to RMB162.6 million, while adjusted net loss fell 12.6% to RMB130.1 million. During the period, Alebund completed enrollment in the global Phase III trial for AP301, and the NMPA accepted its New Drug Application for review in August 2026. The company also listed on the Hong Kong Stock Exchange in June, raising net proceeds of approximately HK$1,355.8 million, including the over-allotment option. Cash and equivalents stood at RMB1,392.8 million as of June 30, 2026.